Investigational Drug Information for IMP4297
✉ Email this page to a colleague
What is the drug development status for IMP4297?
IMP4297 is an investigational drug.
There have been 12 clinical trials for IMP4297.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 24th 2019.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Prostatic Neoplasms. The leading clinical trial sponsors are Impact Therapeutics, Inc., Sponsor GmbH, and Shanghai Junshi Bioscience Co., Ltd.
There are forty-nine US patents protecting this investigational drug and forty-four international patents.
Summary for IMP4297
| US Patents | 49 |
| International Patents | 44 |
| US Patent Applications | 131 |
| WIPO Patent Applications | 116 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 1 (2019-12-24) |
| Vendors | 30 |
Recent Clinical Trials for IMP4297
| Title | Sponsor | Phase |
|---|---|---|
| An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition | Impact Therapeutics, Inc. | Phase 1 |
| An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition | Impact Therapeutics, Inc. | Phase 1 |
| A Study Explore JS001+IMP4297 in Patients With Advanced Cancer | Sponsor GmbH | Phase 1 |
Clinical Trial Summary for IMP4297
Top disease conditions for IMP4297
Top clinical trial sponsors for IMP4297
US Patents for IMP4297
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| IMP4297 | ⤷ Start Trial | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | Impact Therapeutics Inc | ⤷ Start Trial |
| IMP4297 | ⤷ Start Trial | Process for the preparation of 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones | Impact Therapeutics Inc , Impact Therapeutics Shanghai Inc | ⤷ Start Trial |
| IMP4297 | ⤷ Start Trial | Solid pharmaceutical formulation of PARP inhibitors and use thereof | Impact Therapeutics Inc , Impact Therapeutics Shanghai Inc | ⤷ Start Trial |
| IMP4297 | ⤷ Start Trial | 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof | Impact Therapeutics Inc , Impact Therapeutics Shanghai Inc | ⤷ Start Trial |
| IMP4297 | ⤷ Start Trial | Substituted eneoxindoles and uses thereof | Gilead Sciences Inc | ⤷ Start Trial |
| IMP4297 | ⤷ Start Trial | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors | Array Biopharma Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for IMP4297
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| IMP4297 | Australia | AU2012237776 | 2031-04-01 | ⤷ Start Trial |
| IMP4297 | Canada | CA2831015 | 2031-04-01 | ⤷ Start Trial |
| IMP4297 | China | CN102731416 | 2031-04-01 | ⤷ Start Trial |
| IMP4297 | China | CN103097361 | 2031-04-01 | ⤷ Start Trial |
| IMP4297 | China | CN104230827 | 2031-04-01 | ⤷ Start Trial |
| IMP4297 | Denmark | DK2709990 | 2031-04-01 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
